AI Article Synopsis
- The GAFCHROMIC(®) EBT2 dosimetry film is used as a fast quality control tool for mapping 2D dose profiles in BNCT beams at THOR.
- The film's pixel values are converted to dose profiles using a calibration curve from 6-MV X-ray, with preliminary results showing acceptable reproducibility (±2 to ±3.5% uncertainties).
- The EBT2 film measures both gamma-ray and neutron contributions, indicating that its dose profile differs from neutron flux profiles, highlighting the need for further research on neutron effects for accurate dose measurements in BNCT beams.
Article Abstract
The GAFCHROMIC(®) EBT2 dosimetry film has been studied as a rapid QC/QA tool for 2D dose profile mapping in the BNCT beam at THOR. The pixel values of the EBT2 film image were converted to the 2D dose profile using a dose calibration curve obtained by 6-MV X-ray. The reproducibility of the 2D dose profile measured using the EBT2 film in the PMMA phantom was preliminarily found to be acceptable with uncertainties within about ±2 to ±3.5%. It is found that the EBT2 measured dose profile consisted of both gamma-ray components and neutron contributions. Therefore, the dose profile measured using the EBT2 film is significantly different from the neutron flux profile measured using the indirect neutron radiography method. Further study of the influence of neutrons to the response of the EBT2 film is indispensible for the absolute dose profile determination in a BNCT beam.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.apradiso.2011.04.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The prognosis for patients with acute promyelocytic leukemia (APL) has improved dramatically since the introduction of all-trans retinoic acid (ATRA) and intravenous arsenic trioxide (ATO). However, ATO administration requires daily infusions over several months, representing an onerous burden for hospitals and patients. We evaluated the bioavailability of a novel encapsulated oral ATO formulation in APL patients in first complete remission during standard-of-care consolidation.
View Article and Find Full Text PDFDeciphering the dose-dependent effects of thymoquinone on cellular proliferation and transcriptomic changes in A172 glioblastoma cells.
PLoS One
January 2025
Department of Biology, West Virginia State University, Institute, WV, United States of America.
Glioblastoma multiforme (GBM), the most prevalent primary malignant brain tumor in adults, exhibits a dismal 6.9% five-year survival rate post-diagnosis. Thymoquinone (TQ), the most abundant bioactive compound in Nigella sativa, has been extensively researched for its anticancer properties across various human cancers.
View Article and Find Full Text PDFLong-term safety and efficacy of fostamatinib in Japanese patients with primary immune thrombocytopenia.
Int J Hematol
January 2025
Department of Blood Transfusion, Osaka University Hospital, Osaka, Japan.
Fostamatinib had superior efficacy to a placebo and acceptable safety profiles for at least 1 year in a phase 3 study of Japanese patients with primary immune thrombocytopenia. Here, we report the 3-year safety and efficacy of fostamatinib in that study. Data from 33 patients who received at least one dose of fostamatinib were analyzed.
View Article and Find Full Text PDFFeeding broilers with the addition of an Ilex paraguariensis coproduct affects zootechnical performance and meat quality responses.
Trop Anim Health Prod
January 2025
Department of Agroindustrial Science and Technology, Federal University of Pelotas, Rio Grande Do Sul, Brazil.
During the harvest of Ilex paraguariensis, approximately 2-5 tons per hectare of thick stems are left on the soil surface. The outer portion of these stems, referred to as the coproduct, constitutes 30% of the total residue mass. Although this coproduct has been partially characterized in terms of its phytochemical profile, its technological applications remain unexplored.
View Article and Find Full Text PDFTofacitinib Treatment for Active Dermatomyositis and Anti-synthetase Syndrome: A Prospective Cohort Pilot Study.
Rheumatology (Oxford)
January 2025
Department of Rheumatology and Immunology and Beijing Key Laboratory for Rheumatism and Immune Diagnosis (BZ0135), Peking University People's Hospital, Beijing, 100044, China.
Objectives: The objective of this study was to evaluate the efficacy and safety of tofacitinib in the treatment of active dermatomyositis (DM) and anti-synthetase syndrome (ASS).
Methods: Tofacitinib was administered at a dose of 5 mg twice daily to patients who exhibited inadequate response to conventional treatments. The primary end point was the reduction of T follicular helper (Tfh) cells at week 24.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!